Publications

 


  • 68. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml PSA.

    Lodding P, Aus G, Bergdahl S, Frösing R, Lilja H, Pihl CG, Hugosson J., 1998

    Journal: J of Urol
    Reference: 159:899-903.

    paper

  • 67. Repeat screening for prostate cancer after 1-year follow-up in 984 biopsied men. Clinical and pathological features of detected cancers.

    Rietbergen JWB, Boeken Kruger AE, Hoedemaeker RF, Bangma ChH, Kirkels WJ, Schröder F.H., 1998

    Journal: J Urol
    Reference: 160 (6 Pt 1):2121-5

    paper

  • 66. Screening for prostate cancer. More questions than answers.

    Rietbergen JWB, Schröder FH., 1998

    Journal: Acta Oncologica
    Reference: 37(6):515-32.

    paper

  • 65. Evaluation of the Digital Rectal Examination (DRE) as a screening test for prostate cancer.

    Schröder FH, Van der Maas PJ, Beemsterboer PMM, Boeken Kruger AE, Hoedemaeker RF, Rietbergen JWB, Kranse R., 1998

    Journal: JNCI
    Reference: 90(23):1817-23.

    paper

  • 64. Comparison of PSA corrected for total prostate volume and transition zone volume in a population-based screening study.

    Rietbergen JWB, Kranse R, Hoedemaeker RF, Boeken Kruger AE, Bangma CH, Kirkels WJ, Schröder FH., 1998

    Journal: Urol
    Reference: 52(2):237- 246.

    paper

  • 63. Tumorcontrole bij patiënten met niet gemetastaseerd prostaat carcinoom, behandeld met radicale prostatectomie: een prospectieve studie.

    Van den Ouden D, Hop WJC, Kranse R, Schröder FH., 1998

    Journal: NTvG
    Reference: 142(7):349-354.

  • 62. De behandeling van lokaal uitgebreid (T3) prostaatcarcinoom met radicale prostatectomie of radiotherapie. Een overzicht.

    Ouden D van den, Schröder FH., 1998

    Journal: Tijdschr Gerontologie en Geriatrie
    Reference: 29:74-79.

  • 61. Leeftijd als prognostische factor bij patiënten met niet-gemetastaseerd prostaatcarcinoom, behandeld met radicale prostatectomie: een prospectief onderzoek.

    Ouden D van den, Hop WCJ, Schröder FH., 1998

    Journal: Ned Tijdsch Urol
    Reference: 4:70-76.

  • 60. Editorial comment on: Percentage of free serum prostate- specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Arcangeli CG, Humphrey PA, Smith DS, Harmon TJ, Shepherd DL. Keetch DW, Catalona WJ.

    Schröder FH, Kranse R., 1998

    Journal: Urology
    Reference: 51(4):564-565.

    paper

  • 59. Progression and survival in patients with locally confined advanced prostate cancer (T3) treated by radical prostatectomy as a monotherapy.

    Ouden D van den, Hop WCJ, Schröder FH., 1998

    Journal: J Urol
    Reference: 160:1392-1397.

    paper

  • 58. Microvascular invasion in prostate cancer: prognostic significance in patients treated by radical prostatectomy for clinically localized carcinoma.

    Ouden D van den, Kranse R, Hop WCJ, Kwast ThH van der, Schröder FH., 1998

    Journal: Urol Int
    Reference: 60:17-24.

    paper

  • 57. Standaardisatie van de bepaling van PSA: stand van zaken anno 1997.

    Blijenberg BG, Van Zelst B, Schröder FH., 1998

    Journal: Ned Tijdschrift Klin Chem
    Reference: 23:8-12.

  • 56. Risk factors for progression in patients with prostate cancer treated by radical prostatectomy. 2

    Boeken Kruger AE, Schröder FH., 1997

    Journal: Current opinion in Urology
    Reference: 7:186-9.

    paper

  • 55. The European Randomized Study of Screening for Prostate Cancer (ERSPC).

    Schröder FH, Bangma CH., 1997

    Journal: BJU
    Reference: (79, suppl. 1):68-71

    paper

  • 54. Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis.

    Gerber GS, Thisted RA, Chodak GW, Schröder FH, Frohmüller HW, Scardino PT, Paulson DF, Middleton Jr AW, Rukstalis DB, Smith Jr JA, Ohori M, Theiss M, Schelhammer PF., 1997

    Journal: Eur Urol
    Reference: 32:385-390.

    paper

  • 53. Analytical evaluation of the new Prostatus TM free/total assay for prostate-specific antigen as a part of screening study for prostate cancer.

    Blijenberg BG, Bangma CH, Kranse R, Eman I, Schröder FH., 1997

    Journal: Eur J Clin Chem Biochem
    Reference: 35(2):111-114.

    paper

  • 52. A comparison of disease specific survival of patients who died of and who had newly diagnosed prostate cancer.

    Boer R, Koning HJ de, Beemsterboer P, Warmerdam PG, Schröder FH., 1997

    Journal: J Urol
    Reference: 157:1768-1772.

    paper

  • 51. Diagnosis of ProstateCancer: Optimal Number of Prostate Biopsies Related to Serum Prostate-Specific Antigen and Findings on Digital Rectal Examination.

    Aus G, Ahlgren G, Hugosson J, Pedersen KV, Rensfeldt K, Söderberg R., 1997

    Journal: Scand J Urol Nephrol
    Reference: 31:541-544.

    paper

  • 50. Risk factors for progression in patients with prostate cancer treated by radical prostatectomy.

    Boeken Kruger AE, Schröder FH., 1997

    Journal: Current opinion in Urology
    Reference: 7:186-189.

    paper

  • 49. The European Randomized Study of Screening for Prostate Cancer: an update.

    Standaert B, Denis LJ., 1997

    Journal: Cancer
    Reference: 80(9):1830-34.

  • 48. Prostate volume and cancer in screening programs.

    Standaert B, Alwan A, Nelen V, Denis LJ., 1997

    Journal: The Prostate
    Reference: 33:188-94.

    paper

  • 47. Multitest’ screeningsonderzoek op prostaatkanker in Antwerpen.

    Standaert B, Alwan A, Dourcy-Belle-Rose B, Van Oeckel P, Maes N, Nelen V, Wauters A, Neels H, Denis L., 1997

    Journal: Tijdschrift voor Geneeskunde
    Reference: 53(13):867-74.

    paper

  • 46. Comparison of pathological characteristics of T1c and non-T1c cancers detected in a population based screening study, the European Randomized Study of Screening for Prostate Cancer.

    Hoedemaeker RF, Rietbergen JBW, Kranse R, Van der Kwast ThH, Schröder F., 1997

    Journal: World J Urol
    Reference: 15:339-345.

    paper

  • 45. Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate.

    Van den Ouden D, Hop WCJ, Kranse R, Schröder FH., 1997

    Journal: Br J of Urology
    Reference: 79:203-11.

    paper

  • 44. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma.

    Bangma CH, Kranse R, Blijenberg BG, Schröder FH., 1997

    Journal: J of Urology
    Reference: 157:544-7.

    paper

  • 43. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program.

    Rietbergen JBW, Boeken Kruger AE, Kranse R, Schröder FH., 1997

    Journal: Urology
    Reference: 49(6):875-80.

    paper

  • 42. Free and total PSA in a screened population.

    Bangma CH, Blijenberg BG, Schröder FH., 1997

    Journal: Br J Urology
    Reference: 79(5):756-62

    paper

  • 41. Prostate-specific antigen as a screening test – The Netherlands experience

    Bangma CH, Rietbergen JBW, Schröder FH., 1997

    Journal: Urol Clin North Am
    Reference: 24(2):307-14.

    paper

  • 40. Randomised trials of prostate cancer screening in the Netherlands: assessment of acceptance and motives for attendance.

    Nijs HTG, Tordoir DMR, Schuurman JH, Kirkels WJ, Schröder FH., 1997

    Journal: J of Med Screening
    Reference: 4:102-6

    paper

  • 39. The free-to total prostate-specific antigen ratio improves the specificity of PSA in screening for prostate cancer in the general population.

    Bangma CH, Rietbergen JBW, Kranse R, Blijenberg BG, Pettersson K, Schröder FH., 1997

    Journal: J Urol
    Reference: 157:2191-2196.

    paper

  • 38. Adenocarcinoma of the Prostate: Innovations in Management.

    Petrovich Z, Baert L, Bagshaw MA, Brady LW, Elgamal A, Goethuys H, Heilman HP, Kirkels WJ, Lieskovsky G, Perez CA, Van Poppel H, Williams RD., 1997

    Journal: Am. J Clin Oncol
    Reference: 20(2):111-119.

    paper

  • 37. Evaluation of prostate specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer: improving the efficiency of early detection.

    Rietbergen JWB, Kranse R, Kirkels WJ, De Koning HJ, Schröder FH., 1997

    Journal: BJU
    Reference: (2) suppl. 2:57-63.

    paper

  • 36. Screening for prostate cancer using serum prostate specific antigen: a randomised, population-based pilot study in Finland.

    Auvinen A, Tammela T, Stenman U-H, Uusi-Erkkilä I, Schröder FH, Hakama M., 1996

    Journal: Br J Cancer.
    Reference: 74:568-572.

    paper

  • 35. Screening del cáncer de próstata: un problema no resuelto.

    Berenguer A., 1996

    Journal: Actas Urol Esp
    Reference: 20:768-771.

    paper

  • 34. Screening del cáncer de próstata: estudio en una población española.

    Herrero Payo JA, Montes Diaz J, Paez Borda A, Sánchez Sánchez E, Moreno Valle Y JA, Berenguer Sanchez A., 1996

    Journal: Archivos Esp Urol
    Reference: 49(6):595-606.

    paper

  • 33. Surveillance is not a viable and appropriate treatment option in the management of localized prostate cancer.

    Hugosson J, Aus G, Norlén L., 1996

    Journal: The Urol Clinics of N. America
    Reference: 23(4):557-573.

    paper

  • 32. Problems in the Determination of Prostate Specific Antigen.

    Stenman UH, Leinonen J, Zhang WM., 1996

    Journal: Eur J Clin Biochem
    Reference: 34:735-740.

    paper

  • 31. Prospective evaluation plan for randomised trials of prostate cancer screening.

    Auvinen A, Rietbergen JBW, Denis LJ, Schröder FH, Prorok PC., 1996

    Journal: J Med Screening
    Reference: 3(2):97-104

    paper

  • 30. Some analytical considerations on the measurement of prostate-specific antigen.

    Blijenberg BG, Kranse R, Eman I, Schröder FH., 1996

    Journal: Eur. J. Clin. Chem. Clin. Biochem.
    Reference: 34(10):817-21.

    paper

  • 29. Radical Prostatectomy: prospective assessment of mortality and morbidity.

    Davidson PJT, Van den Ouden D, Schröder FH., 1996

    Journal: Eur. Urol
    Reference: 29;168-173.

    paper

  • 28. European randomized study of screening for prostate cancer – The Rotterdam pilot studies.

    Schröder FH, Damhuis RAM, Kirkels WJ, De Koning HJ, Kranse R, Nijs HGT, Blijenberg BG., 1996

    Journal: International J of Cancer
    Reference: 65:145-151.

    paper

  • 27. Free serum prostate-specific antigen and screening for prostate cancer.

    Bangma CH, Kranse R, Schröder FH., 1996

    Journal: J Am Med Assoc
    Reference: 275(11):837-838.

  • 26. Evidence and feasibility of prostate cancer screening.

    Ciatto S, Bonardi R, Mazzotta A, Zappa M., 1995

    Journal: The Cancer Journal
    Reference: 8:33-35.

    paper

  • 25. Detection of prostate cancer, screening the whole population has not yet been shown to be worth while

    Schröder FH., 1995

    Journal: (letter to the editor).
    Reference: 310:140-1.

    paper

  • 24. Diagnosing benign prostatic hyperplasia versus prostate cancer.

    Denis LJ., 1995

    Journal: BJU
    Reference: 76(suppl. 1):17-23.

    paper

  • 23. “Prostate Cancer screening and prevention: “Realities and Hope”.

    Denis LJ., 1995

    Journal: Urology
    Reference: 46(suppl. 3a):56-61.

    paper

  • 22. Prostate Cancer: a continuum of controversy.

    Denis LJ., 1995

    Journal: Eur J Cancer
    Reference: 31A(5):839-40.

    paper

  • 21. Comparing two modalities of screening for prostate cancer: digital rectal examination and transrectal ultrasonography vs. prostate specific antigen.

    Ciatto S, Bonardi R, Mazzotta A, Lombardi C, Santoni R, Cardini S, Zappa M., 1995

    Journal: Tumori
    Reference: 81:225-229.

    paper

  • 20. Eliminating the need for per-operative frozen section analysis of pelvic lymph nodes during radical prostatectomy.

    Bangma CH, Hop WCJ, Schröder FH., 1995

    Journal: BJU
    Reference: 76:595-599.

    paper

  • 19. Multicentre evaluation of a new fully automated enzyme immunoassay for total prostate-specific antigen.

    Blijenberg BG, Kessler A-C, Uhl W., 1995

    Journal: Eur J Clin Chem Clin Biochem
    Reference: 33:965 973.

    paper

← PreviousNext →